Exogene

About

Exogene is a biotechnology company accelerating target & TCR discovery for cancer cell therapies using AI-enabled TCR-antigen screening.

London,England,United Kingdom
1 - 10

Highlights

Details

Last Funding Type: Pre-seed
Last Funding Money Raised: $2M
Industries: Artificial Intelligence,Biotechnology,Life Science,Pharmaceutical
Founded date: Nov 1, 2019
Number Of Employee: 1 - 10
Operating Status: Active
Legal Name: Exogene Limited

Exogene is a biotechnology company accelerating the discovery of T-cell-receptor(TCR)-based cancer immunotherapies for solid tumours by combining deep learning and high-throughput TCR-antigen screening. Exogene is building a computational platform to quickly and inexpensively identify new tumour targets shared across cancer patients, as well as safe and effective TCRs against these tumour targets for therapeutic application. Their mission is to develop better TCR-based immunotherapies, faster and at a fraction of the cost.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

2

$2M £80K

Exogene has raised a total of $2M £80K in funding over 2 rounds. Their latest funding was raised on Apr 25, 2022 from a Pre-seed round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Apr 25, 2022	Pre-seed	$2M	7	Selvedge Venture	—	Detail
Feb 1, 2020	Convertable Note	£80K	1	—	—	Detail

Investors

Number of Lead Investors

Number of Investors

1

7

Exogene is funded by 7 investors. Selvedge Venture and KQ Labs are the most recent investors.

Investor Name	Lead Investor	Funding Round
Selvedge Venture	Yes	Pre-seed
KQ Labs	—	Pre-seed
Entrepreneur First	—	Pre-seed
Jude Gomila	—	Pre-seed
Nadav Rosenberg	—	Pre-seed
R42 Group	—	Pre-seed
Stefano Bernardi	—	Pre-seed